PR
PRTC.LSE PureTech Health plc
- Market cap
- GBX 304M
- P/E
- -
- P/B
- 1.01x
- ROE
- 67.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is PRTC.LSE undervalued?
Graham numberThe Graham number of PureTech Health plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PureTech Health plc fundamental analysis
No fundamental analysis for PureTech Health plc yet.
PureTech Health plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PureTech Health plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnano…
Full company profilePureTech Health plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PureTech Health plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.43M | 650K | 16.4M | 8.69M | 8.34M | 9.98M | 2.09M | 750K | 4.32M | 4.66M | 13.9M |
| Gross Profit | -36.8M | -70.4M | -61.0M | -77.2M | 8.34M | -100M | -137M | -92.9M | 4.32M | 1.34M | 7.50M |
| Operating Income | -73.9M | -115M | -104M | -135M | -120M | -150M | -198M | -146M | -136M | -101M | -205M |
| EBITDA | -77.4M | -67.9M | -65.3M | 488M | -113M | -47.0M | -79.9M | -17.7M | 37.4M | -97.2M | -199M |
| Net Income | -48.8M | -70.7M | -70.7M | 421M | 5.99M | -60.6M | -50.4M | -65.7M | 53.5M | -110M | 264M |
| EPS | -0.21 | -0.30 | -0.26 | 1.44 | 0.02 | -0.21 | -0.18 | -0.24 | 0.20 | -0.46 | 1.06 |
| Balance Sheet | |||||||||||
| Total Assets | 299M | 340M | 442M | 941M | 990M | 946M | 703M | 694M | 603M | 535M | 641M |
| Total Liabilities | 206M | 276M | 275M | 291M | 336M | 362M | 155M | 236M | 195M | 229M | 259M |
| Shareholders' Equity | 178M | 214M | 276M | 668M | 670M | 594M | 542M | 464M | 415M | 312M | 388M |
| Cash & Short-term Investments | 282M | 190M | 251M | 162M | 404M | 466M | 350M | 327M | 367M | 279M | 223M |
| Total Debt | 6.95M | 7.46M | 12.4M | 39.3M | 76.6M | 52.7M | 46.9M | 25.3M | 159M | 19.8M | 18.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -58.0M | -88.7M | -72.8M | -98.2M | -132M | -158M | -179M | -106M | -134M | -86.9M | -174M |
| Capital Expenditure | 3.68M | 2.17M | 4.49M | 12.5M | 5.42M | 5.66M | 2.18M | 245K | 11.0K | 6.13K | 15.84 |
| Free Cash Flow | -61.7M | -90.9M | -77.3M | -111M | -137M | -164M | -181M | -106M | -134M | -86.9M | -174M |
| Ratios | |||||||||||
| ROE | -27.5% | -33.0% | -25.6% | 63.0% | 0.9% | -10.2% | -9.3% | -14.2% | 12.9% | -35.2% | 67.9% |
| ROA | -16.3% | -20.8% | -16.0% | 44.7% | 0.6% | -6.4% | -7.2% | -9.5% | 8.9% | -20.5% | 41.2% |
| Net Profit Margin | -1,101.2% | -10,876.5% | -431.6% | 4,847.4% | 71.8% | -606.9% | -2,409.3% | -8,759.6% | 1,240.1% | -2,355.4% | 1,890.6% |
| Debt to Equity | 0.04x | 0.03x | 0.04x | 0.06x | 0.11x | 0.09x | 0.09x | 0.05x | 0.38x | 0.06x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PureTech Health plc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 4.03M | 0.01 | - |
| 2021 | USD 5.96M | 0.02 | - |
| 2020 | - | - | - |
| 2019 | USD 112K | 0.00 | 0.0% |
| 2018 | USD 1.07M | 0.00 | - |
| 2017 | USD 91.0K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns PureTech Health plc
- Insiders 10.00%
- Institutions 56.83%
- Public & others 33.17%
- Shares outstanding 245M
- Free float 149M
PureTech Health plc company profile
- Company name
- PureTech Health plc
- Ticker
- PRTC.LSE
- ISIN
- GB00BY2Z0H74
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 90
- Fiscal year end
- December
- Address
- 6 Tide Street, Boston, MA, United States, 02210
- Phone
- 617 482 2333
- Website
- puretechhealth.com
About PureTech Health plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.
PureTech Health plc management
10- Mr. Robert Lyne J.D., L.L.B.CEO & Director · born 1983
- Dr. Robert S. Langer Jr., Ph.D., ScDCo-Founder & Non-Executive Director · born 1949
- Dr. Eric Elenko Ph.D.Co-founder · born 1973
- Dr. David R. Elmaleh Ph.D.Co-Founder & Senior Advisor · born 1948
- Ms. Lauren A. White M.B.A.Chief Financial Officer · born 1979
- Mr. Michael Inbar CPA, M.B.A.Chief Accounting Officer
- Ms. Allison Mead TalbotSenior VP of Communications & Head of Investor Relations
- Ms. Aleksandra Filipovic M.D., Ph.D.Head of Oncology
- Ms. Joy Bauer M.S., RDNChief Nutrition Officer
- Dr. Camilla S. Graham M.D., M.P.H.Senior Vice President of Medical Affairs